Breast cancer is the most commonly diagnosed cancer worldwide and is one of the leading
causes of cancer death. The incidence, pathological features, and clinical outcomes in …

Simple Summary Gene expression signatures were initially developed to take into account
tumor biology for adjuvant chemotherapy decision and have become a standard option in …

The development of novel nanoparticle-based drug delivery systems (nano-DDSs) with high
loading capacity, low toxicity, precise targeting, and excellent biocompatibility remains …

Racial disparities are most accentuated among Black women as their lifetime risk of breast
cancer incidence is lower than white and Asian women but their breast cancer related …

Ethnic or racial differences in breast cancer (BC) survival outcomes have been reported, but
current data are largely restricted to comparisons between African Americans and non …

Molecular profiling of breast cancer has enabled the development of more robust molecular
prognostic signatures and therapeutic options for breast cancer patients. However, non …

Background Endocrine treatment is recommended by clinical guidelines as the preferred
treatment option for premenopausal as well as postmenopausal women with hormone …

Introduction This study aimed to describe the latest epidemiology of female breast cancer
globally, analyze the change pattern of the incidence rates and the disease's association …

Importance In the phase 3 KEYNOTE-522 study, addition of pembrolizumab to neoadjuvant
chemotherapy followed by adjuvant pembrolizumab significantly increased pathologic …

Pembrolizumab plus chemotherapy improved progression‐free survival (PFS) and overall
survival (OS) compared with placebo plus chemotherapy in patients with previously …